Anika Therapeutics, Inc.
$197.18M- Market cap
- $278.50M
- Debt
- +-$149.00K
- Cash
- −$81.17M
Capital structure 100% equity / -0% debt · EV / Revenue 1.75x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: ANIK stock price at discount vs ASML $20.81 current versus $146.76 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ASML's multiple
Implied fair value · at ANIK's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ANIK FY 2025 (ended Dec 31, 2025) · ASML FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / -0% debt · EV / Revenue 1.75x
Capital structure 99% equity / 1% debt · EV / Revenue 17.15x · EV / EBITDA 43.84x
ASML carries the larger enterprise value at $651.04B against $197.18M; ANIK trades on the lower EV / Revenue multiple (1.75x vs 17.15x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Anika Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
ASML HOLDING NV · implied price per share
Bear
$441.98
Base
$539.51
Bull
$615.36
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-0.00x
0.22x
Net debt / EBITDA
Leverage against operating earnings
34.65x
-0.67x
Cash and equivalents
Liquid reserves on the balance sheet
$81.17M
$12.92B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ZIMMER BIOMET HOLDINGS, INC.
ANIK vs ZBH
STRYKER CORP
ANIK vs SYK
BECTON DICKINSON & CO
ANIK vs BDX
INTEGRA LIFESCIENCES HOLDINGS CORP
ANIK vs IART
APPLIED MATERIALS INC /DE
ANIK vs AMAT
LAM RESEARCH CORP
ANIK vs LRCX
KLA CORP
ANIK vs KLAC
TERADYNE, INC
ANIK vs TER
ENTEGRIS INC
ANIK vs ENTG
-$149.00K
$4.39B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.